Markus Müschen, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Markus Müschen, MD, PhD

Professor, Department of Laboratory Medicine, UCSF
Program Co-Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center

markus.muschen@ucsf.edu

Phone: (415) 502-0388 (voice)
Box 0134, UCSF
San Francisco, CA 94143-0134

View on UCSF Profiles

Cancer Center Membership

Program Member » Hematopoietic Malignancies

Research Summary

ACTIVE RESEARCH SUPPORT

R01CA137060-A1 Müschen (PI) 04/01/2008 - 12/31/2012

NCI/NIH

“Pre-B cell receptor signaling in acute lymphoblastic leukemia”. The central goal of this project is to clarify the role of pre-B cell receptor signaling in acute lymphoblastic leukemia.

R01CA139032 Müschen (PI) 04/01/2008 - 12/31/2012

NCI/NIH

“AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia”. The central goal is (1) to identify the regulatory mechanisms that lead to aberrant expression of AID and (2) to identify the consequences of aberrant AID-activity in leukemia cells.

1R01CA157644 Müschen (PI) 04/01/2011-03/31/2016

NIH/NCI

‘Infectious origins of childhood leukemia’. The central goal of this proposal is to experimentally test the ‘delayed infections hypothesis’ in the etiology of childhood ALL and to delineate mechanisms of genetic vulnerability of human pre-B cells in the context of infection.

R21CA152497 Müschen (PI) 06/01/2010 - 05/31/2012

NCI/NIH

“Mechanism of BCL6-dependent stem cell maintenance in B cell lineage leukemia”. The central goals of this proposal are (1) to clarify the role of BCL6 in leukemia-initiation of Ph+ ALL and (2) To determine the frequency and phenotype of BCL6-dependent leukemia stem cells.

TR2-01816 Müschen (PI) 10/01/2010-09/30/2013

California Institute for Regenerative Medicine (CIRM)

Early Translation Award. Development of a BCL6 small molecule inhibitor for targeted eradication of leukemia stem cells. The main goals of this project are (1) computer aided drug-design of BCL6 lateral groove inhibitors, (2) PK/PD assays and SAR studies of identified lead compound series and (3) pre-clinical validation.

AACR 138564 Müschen (PI) 12/01/2009 - 11/30/2012

AACR Stand Up To Cancer Innovation Award

Stand Up To Cancer Innovation Award: Role of BCL6 in leukemia stem cell self-renewal. The main goal of this project is to study the role of BCL6 in the maintenance of leukemia-initiating cells in ALL.

LLS 1497-11 Müschen (PI) 10/01/2010-09/30/2015

The Leukemia and Lymphoma Society Scholar Award

Leukemia and Lymphoma Society Scholar Award, will cover salary expenses related to NIH grant R01CA137060 ‘Pre-B cell receptor signaling in acute lymphoblastic leukemia’.

LLS 6132-09 Müschen (PI) 10/01/2008-09/30/2012

The Leukemia and Lymphoma Society

Translational Research Grant ‘Targeting AID in BCR-ABL1-driven leukemia’. The main goal of this project is to study the role of AID in aberrant somatic hypermutation as a cause of genetic instability.

LLS 6097-10 Müschen (PI) 07/01/2009-06/30/2013

The Leukemia and Lymphoma Society

Translational Research Grant ‘BCL6 in oncogene-induced senescence’. The main goal of this project is to study the role of BCL6 in oncogene-induced senescence in MYC-driven B cell lymphoma.

LLS 7005-11 Müschen (Project-PI) 10/01/2010-09/30/2015

Leukemia and Lymphoma Society SCOR

Project 2: Dual targeting of tyrosine kinase and feedback signaling in leukemia. Goals are identification of novel oncogenic tyrosine kinases and characterization of feedback mechanisms in response to tyrosine kinase inhibition. Brian J Druker, Portland, OR is the PI of the SCOR.

LLS 7005-11 Müschen (Project-PI) 10/01/2010-09/30/2015

Leukemia and Lymphoma Society SCOR

Core E: (1) Generate and make xenografted samples available to SCOR projects, (2) Generate a centralized multidimensional database which links flow cytometry data, cytogenetics, gene expression, SNP chip analysis and clinical information. Brian J Druker, Portland, OR is the PI of the SCOR.

Education

University of Nantes, Nantes, France, B.Sc., 1996, Immunology
Institut Pasteur, Paris, France, 1997, Immunology
Heinrich-Heine-Universität Düsseldorf, MD/PhD, 1999, Molecular Biology
University of Cologne, Germany, Intern/Resident, 1999, Hematology/Oncology
Institute for Genetics, University of Cologne, Postdoc, 2000, Genetics
University of Chicago, IL, Postdoc, 2001, Molecular Genetics
University of Cologne, Germany, Postdoc, 2002, Immunology


Professional Experience

  • 1994-1999
    Doctoral thesis in Biochemistry and Molecular Biology, summa cum laude (Mentor: Helmut Sies)
  • 1997-1999
    Internship and Residency in Hematology and Oncology (Mentor: Volker Diehl)
  • 1999-2000
    Postdoctoral fellow, Institute for Genetics, Cologne (Mentor: Klaus Rajewsky and Ralf Küppers)
  • 2000-2001
    Postdoctoral fellow, University of Chicago (Mentor: Janet D Rowley)
  • 2001-2002
    Postdoctoral fellow, Institute for Immunology, Cologne (Mentor: Martin Krönke)
  • 2002-2004
    Assistant Professor of Immunology Associate Professor of Stem Cell Biology (C3; with tenure), Heinrich-Heine-Universität Düsseldorf, Germany
  • 2006-2010
    Associate Professor of Pediatrics, Biochemistry and Molecular Biology, USC; Adjunct Faculty Appointment, Department of Biochemistry and Molecular Biology Program Leader, Leukemia and Lymphoma Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
  • 2006-2010
    Director, Leukemia Research Program, Childrens Hospital Los Angeles, Los Angeles, CA
  • 2010-present
    Professor, Departments of Laboratory Medicine and of Pathology, University of California San Francisco, San Francisco, CA

Honors & Awards

  • 1999
    Doctoral Thesis Award of the German Association for Hematology and Oncology (DGHO)
  • 2000
    Postdoctoral Fellowship Award of the Cancer Research Institute, New York, NY
  • 2001
    Emmy-Noether Young Investigator Award, The German Science Foundation (DFG)
  • 2001
    Stem Cell Research Investigator Award, The State of North-Rhine-Westphalia
  • 2002
    Best Habilitation Thesis of the Year, School of Medicine, University of Cologne, Germany
  • 2003
    Fritz Melchers Award for Immunology, the German Association for Immunology
  • 2006
    Leukemia Clinical Research Award, The German Association for Hematology and Oncology
  • 2006
    Honorary Professor of the Xinxiang Medical University, Xinxiang, P.R. China
  • 2009
    Section Editor for Acute Lymphoblastic Leukemia (ALL), Leukemia
  • 2009-present
    Study section member, Leukemia and Lymphoma Society, DOD Hematologic Malignancies Panel, NYStem (New York Stem Cell Research Agency)
  • 2010
    Editorial Board Biological Chemistry; Associate Editor Blood Cancer Journal
  • 2010-present
    Abstract Reviewer, American Society of Hematology
  • 2010
    Scholar Award, The Leukemia and Lymphoma Society

Selected Publications

  1. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekoffer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LaBoeuf N, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 Apr 11; 29(4):574-86.
    View on PubMed
  2. Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med. 2016 Mar 14.
    View on PubMed
  3. Sun H, Lin DC, Guo X, Masouleh BK, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP. Inhibition of IRE1a-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget. 2016 Feb 25.
    View on PubMed
  4. Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 Feb 10.
    View on PubMed
  5. Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, Lin DC, Bai JW, Mead M, Zhao Z, Chen Q, Chien WW, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell VJ, Koeffler HP. BCOR regulates myeloid cell proliferation and differentiation. Leukemia. 2016 Feb 5.
    View on PubMed
  6. Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016 Feb 5.
    View on PubMed
  7. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015 Dec 16.
    View on PubMed
  8. Song C, Pan X, Ge Z, Gowda C, Ding Y, Li H, Li Z, Yochum G, Muschen M, Li Q, Payne KJ, Dovat S. Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia. Leukemia. 2015 Dec 7.
    View on PubMed
  9. Greaves M, Müschen M. Infection and the Perils of B-cell Activation. Cancer Discov. 2015 Dec; 5(12):1244-6.
    View on PubMed
  10. Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. 2015 Nov 5; 126(19):2202-12.
    View on PubMed
  11. Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH, Wang H, Muthusami S, Ge Z, Sachdev M, Amin SG, Desai D, Gowda K, Gowda R, Robertson GP, Schjerven H, Muschen M, Payne KJ, Dovat S. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood. 2015 Jul 28.
    View on PubMed
  12. Swaminathan S, Müschen M. Infectious origins of childhood leukemia. Oncotarget. 2015 Jul 10; 6(19):16798-9.
    View on PubMed
  13. Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):114-28.
    View on PubMed
  14. Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF, Müschen M. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol. 2015 Jul; 16(7):766-74.
    View on PubMed
  15. Montamat-Sicotte D, Litzler LC, Abreu C, Safavi S, Zahn A, Orthwein A, Müschen M, Oppezzo P, Muñoz DP, Di Noia JM. HSP90 inhibitors decrease AID levels and activity in mice and in human cells. Eur J Immunol. 2015 Aug; 45(8):2365-76.
    View on PubMed
  16. Müschen M. Ph+ ALL: drawing strength from a benign past. Blood. 2015 May 7; 125(19):2879-80.
    View on PubMed
  17. Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. J Hematol Oncol. 2015; 8:39.
    View on PubMed
  18. Müschen M. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood. 2015 Jun 11; 125(24):3688-93.
    View on PubMed
  19. Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015 May 21; 521(7552):357-61.
    View on PubMed
  20. Buchner M, Park E, Geng H, Klemm L, Flach J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P, Müschen M. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nat Commun. 2015; 6:6471.
    View on PubMed

Go to UCSF Profiles, powered by CTSI